Fungal Infections of the Central Nervous System

Current Infectious Disease Reports

Volumn 16, Issue 12, 2014, Pages

  Jacobs, Claire S ^a   Etherton, Mark R ^a   Lyons, Jennifer L ^b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

CNS infection; Cryptococcal meningitis; Cryptococcus; Endemic Fungi; Meningitis; Yeast

Indexed keywords

AMPHOTERICIN B; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE;

AJELLOMYCES CAPSULATUS; AJELLOMYCES DERMATITIDIS; CENTRAL NERVOUS SYSTEM INFECTION; COCCIDIOIDES IMMITIS; CRYPTOCOCCUS GATTII; CRYPTOCOCCUS NEOFORMANS; HUMAN; IMMUNITY; MYCOSIS; NONHUMAN; PARACOCCIDIOIDES BRASILIENSIS; REVIEW; SPOROTHRIX SCHENCKII; TALAROMYCES MARNEFFEI;

EID: 84920260699     PISSN: 15233847     EISSN: 15343146     Source Type: Journal    
DOI: 10.1007/s11908-014-0449-2     Document Type: Review

References (61)

1. Murthy JM, Sundaram C. Fungal infections of the central nervous system. Handb Clin Neurol. 2014;121:1383–401.
2. Clark TA, Hajjeh RA. Recent trends in the epidemiology of invasive mycoses. Curr Opin Infect Dis. 2002;15:569–74.
3. Murthy JM. Fungal infections of the central nervous system: the clinical syndromes. Neurol India. 2007;55:221–5.
4. Marra CM. Bacterial and fungal brain infections in AIDS. Semin Neurol. 1999;19:177–84.
5. Rees JR, Pinner RW, Hajjeh RA, Brandt ME, Reingold AL. The epidemiological features of invasive mycotic infections in the San Francisco Bay area, 1992–1993: results of population-based laboratory active surveillance. Clin Infect Dis: Off Publ Infect Dis Soc Am. 1998;27:1138–47.
6. Schoch CL, Robbertse B, Robert V, Vu D, Cardinali G, Irinyi L, et al. Finding needles in haystacks: linking scientific names, reference specimens and molecular data for Fungi. Database: J Biol Databases Curation. 2014;2014.
7. Park BJ, Wannemuehler KA, Marston BJ, Govender N, Pappas PG, Chiller TM. Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. Aids. 2009;23:525–30.
8. Chang YC, Stins MF, McCaffery MJ, Miller GF, Pare DR, Dam T, et al. Cryptococcal yeast cells invade the central nervous system via transcellular penetration of the blood–brain barrier. Infect Immun. 2004;72:4985–95.
9. Sloan DJ, Parris V. Cryptococcal meningitis: epidemiology and therapeutic options. Clin Epidemiol. 2014;6:169–82.
10. Chen J, Varma A, Diaz MR, Litvintseva AP, Wollenberg KK, Kwon-Chung KJ. Cryptococcus neoformans strains and infection in apparently immunocompetent patients, China. Emerg Infect Dis. 2008;14:755–62.
11. Kwon-Chung KJ, Fraser JA, Doering TL, Wang Z, Janbon G, Idnurm A, et al. Cryptococcus neoformans and Cryptococcus gattii, the etiologic agents of cryptococcosis. Cold Spring Harb Perspect Med. 2014;4:a019760.
12. Chen SC, Slavin MA, Heath CH, Playford EG, Byth K, Marriott D, et al. Clinical manifestations of Cryptococcus gattii infection: determinants of neurological sequelae and death. Clin Infect Dis: Off Publ Infect Dis Soc Am. 2012;55:789–98.
13. Engelthaler DM, Hicks ND, Gillece JD, Roe CC, Schupp JM, Driebe EM, et al. Cryptococcus gattii in North American Pacific Northwest: whole-population genome analysis provides insights into species evolution and dispersal. mBio. 2014;5:e01464–01414. This population-level genome study of C. gattii infections in the Pacific Northwest, an area where the climate was not previously known to harbor this organism, describes environmental origins of the yeast and divergence from previously accepted clinical presentations of C. gattii infections.
14. Harris JR, Lockhart SR, Debess E, Marsden-Haug N, Goldoft M, Wohrle R, et al. Cryptococcus gattii in the United States: clinical aspects of infection with an emerging pathogen. Clin Infect Dis: Off Publ Infect Dis Soc Am. 2011;53:1188–95.
15. Byrnes 3rd EJ, Bartlett KH, Perfect JR, Heitman J. Cryptococcus gattii: an emerging fungal pathogen infecting humans and animals. Microbes Infect / Institut Pasteur. 2011;13:895–907.
16. Saijo T, Chen J, Chen SC, Rosen LB, Yi J, Sorrell TC, et al. Anti-granulocyte-macrophage colony-stimulating factor autoantibodies are a risk factor for central nervous system infection by Cryptococcus gattii in otherwise immunocompetent patients. mBio. 2014;5:e00912–4.
17. Iverson SA, Chiller T, Beekmann S, Polgreen PM, Harris J. Recognition and diagnosis of Cryptococcus gattii infections in the United States. Emerg Infect Dis. 2012;18:1012–5.
18. Perfect JR. Fungal diagnosis: how do we do it and can we do better? Curr Med Res Opin. 2013;29 Suppl 4:3–11.
19. Perfect JR, Dismukes WE, Dromer F, Goldman DL, Graybill JR, Hamill RJ, et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america. Clin Infect Dis: Off Publ Infect Dis Soc Am. 2010;50:291–322.
20. Day JN, Chau TT, Wolbers M, Mai PP, Dung NT, Mai NH, et al. Combination antifungal therapy for cryptococcal meningitis. N Engl J Med. 2013;368:1291–302. This trial of combination flucytosine and amphotericin B or fluconazole and amphotericin B induction for CM compared to amphotericin alone showed significant mortality benefit for the amphotericin B/flucytosine group but not for the fluconazole/amphotericin B group.
21. Boulware DR, Meya DB, Muzoora C, Rolfes MA, Huppler Hullsiek K, Musubire A, et al. Timing of antiretroviral therapy after diagnosis of cryptococcal meningitis. N Engl J Med. 2014;370:2487–98.
22. de Vedia L, Arechavala A, Calderon MI, Maiolo E, Rodriguez A, Lista N, et al. Relevance of intracranial hypertension control in the management of Cryptococcus neoformans meningitis related to AIDS. Infection. 2013;41:1073–7.
23. Phillips P, Chapman K, Sharp M, Harrison P, Vortel J, Steiner T, et al. Dexamethasone in Cryptococcus gattii central nervous system infection. Clin Infect Dis: Off Publ Infect Dis Soc Am. 2009;49:591–5.
24. Shelburne 3rd SA, Darcourt J, White Jr AC, Greenberg SB, Hamill RJ, Atmar RL, et al. The role of immune reconstitution inflammatory syndrome in AIDS-related Cryptococcus neoformans disease in the era of highly active antiretroviral therapy. Clin Infect Dis: Off Publ Infect Dis Soc Am. 2005;40:1049–52.
25. Muller M, Wandel S, Colebunders R, Attia S, Furrer H, Egger M, et al. Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection: a systematic review and meta-analysis. Lancet Infect Dis. 2010;10:251–61.
26. Bahr N, Boulware DR, Marais S, Scriven J, Wilkinson RJ, Meintjes G. Central nervous system immune reconstitution inflammatory syndrome. Curr Infect Dis Rep. 2013;15:583–93.
27. Antinori S. New insights into HIV/AIDS-associated Cryptococcosis. Isrn Aids. 2013;2013:471363.
28. Chang CC, Lim A, Omarjee S, Levitz SM, Gosnell BI, Spelman T, et al. Cryptococcosis-IRIS is associated with lower cryptococcus-specific IFN-gamma responses before antiretroviral therapy but not higher T-cell responses during therapy. J Infect Dis. 2013;208:898–906. This prospective study of 106 HIV patients with CM assessing markers of Cryptococcus-specific immune function before the initiation of cART shows that relative preservation of CM-specific immune function and hence ability to clear infection prior to initiation of cART lowers the risk of developing IRIS.
29. Boulware DR, Bonham SC, Meya DB, Wiesner DL, Park GS, Kambugu A, et al. Paucity of initial cerebrospinal fluid inflammation in cryptococcal meningitis is associated with subsequent immune reconstitution inflammatory syndrome. J Infect Dis. 2010;202:962–70.
30. Siddiqui AA, Brouwer AE, Wuthiekanun V, Jaffar S, Shattock R, Irving D, et al. IFN-gamma at the site of infection determines rate of clearance of infection in cryptococcal meningitis. J Immunol. 2005;174:1746–50.
31. Johnson T, Nath A. Neurological complications of immune reconstitution in HIV-infected populations. Ann N Y Acad Sci. 2010;1184:106–20.
32. Sitapati AM, Kao CL, Cachay ER, Masoumi H, Wallis RS, Mathews WC. Treatment of HIV-related inflammatory cerebral cryptococcoma with adalimumab. Clin Infect Dis: Off Publ Infect Dis Soc Am. 2010;50:e7–10.
33. Saccente M. Central nervous system histoplasmosis. Curr Treat Options Neurol. 2008;10:161–7.
34. Sifuentes-Osornio J, Corzo-Leon DE, Ponce-de-Leon LA. Epidemiology of invasive fungal infections in Latin America. Curr Fungal Infect Rep. 2012;6:23–34.
35. Centers for Disease C, Prevention. Histoplasmosis in a state where it is not known to be endemic—Montana, 2012–2013. MMWR Morb Mortal Wkly Rep. 2013;62:834–7.
36. Trofa D, Nosanchuk JD. Histoplasmosis of the central nervous system. J Neuroparasitol. 2012;3:1–7.
37. Nguyen FN, Kar JK, Zakaria A, Schiess MC. Isolated central nervous system histoplasmosis presenting with ischemic pontine stroke and meningitis in an immune-competent patient. JAMA Neurol. 2013;70:638–41.
38. Mikulska M, Furfaro E, Del Bono V, Raiola AM, Di Grazia C, Bacigalupo A, et al. (1–3)-beta-D-glucan in cerebrospinal fluid is useful for the diagnosis of central nervous system fungal infections. Clin Infect Dis: Off Publ Infect Dis Soc Am. 2013;56:1511–2.
39. Wheat LJ, Freifeld AG, Kleiman MB, Baddley JW, McKinsey DS, Loyd JE, Kauffman CA, Infectious Diseases Society of A. Clinical practice guidelines for the management of patients with histoplasmosis: 2007 update by the Infectious Diseases Society of America. Clin Infect Dis: Off Publ Infect Dis Soc Am. 2007;45:807–25.
40. Saccente M, Woods GL. Clinical and laboratory update on blastomycosis. Clin Microbiol Rev. 2010;23:367–81.
41. Friedman JA, Wijdicks EF, Fulgham JR, Wright AJ. Meningoencephalitis due to Blastomyces dermatitidis: case report and literature review. Mayo Clin Proc. 2000;75:403–8.
42. Bariola JR, Perry P, Pappas PG, Proia L, Shealey W, Wright PW, et al. Blastomycosis of the central nervous system: a multicenter review of diagnosis and treatment in the modern era. Clin Infect Dis: Off Publ Infect Dis Soc Am. 2010;50:797–804.
43. Bush JW, Wuerz T, Embil JM, Del Bigio MR, McDonald PJ, Krawitz S. Outcomes of persons with blastomycosis involving the central nervous system. Diagn Microbiol Infect Dis. 2013;76:175–81.
44. Chapman SW, Dismukes WE, Proia LA, Bradsher RW, Pappas PG, Threlkeld MG, Kauffman CA, Infectious Diseases Society of A. Clinical practice guidelines for the management of blastomycosis: 2008 update by the Infectious Diseases Society of America. Clin Infect Dis: Off Publ Infect Dis Soc Am. 2008;46:1801–12.
45. Marsden-Haug N, Goldoft M, Ralston C, Limaye AP, Chua J, Hill H, et al. Coccidioidomycosis acquired in Washington State. Clin Infect Dis: Off Publ Infect Dis Soc Am. 2013;56:847–50.
46. Litvintseva AP, Marsden-Haug N, Hurst S, Hill H, Gade L, Driebe EM, Ralston C, Roe C, Barker BM, Goldoft M, Keim P, Wohrle R, Thompson GR, 3rd, Engelthaler DM, Brandt ME, Chiller T. 2014. Valley Fever: Finding new places for an old disease: Coccidioides immitis found in Washington State soil associated with recent human infection. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. This is a CDC report on discovery of Coccidioides immitis in regions outside its previously acknowledged endemic habitat of the hot, dry Southwest.
47. Lammering JC, Iv M, Gupta N, Pandit R, Patel MR. Imaging spectrum of CNS coccidioidomycosis: prevalence and significance of concurrent brain and spinal disease. AJR Am J Roentgenol. 2013;200:1334–46.
48. Zunt JR, Baldwin KJ. Chronic and subacute meningitis. Continuum. 2012;18:1290–318.
49. Arsura EL, Johnson R, Penrose J, Stewart K, Kilgore W, Reddy CM, et al. Neuroimaging as a guide to predict outcomes for patients with coccidioidal meningitis. Clin Infect Dis: Off Publ Infect Dis Soc Am. 2005;40:624–7.
50. Ragland AS, Arsura E, Ismail Y, Johnson R. Eosinophilic pleocytosis in coccidioidal meningitis: frequency and significance. Am J Med. 1993;95:254–7.
51. de Almeida SM. Central nervous system paracoccidioidomycosis: an overview. Braz J infect Dis: Off Publ Braz Soc Infect Dis. 2005;9:126–33.
52. de Almeida SM, Queiroz-Telles F, Teive HA, Ribeiro CE, Werneck LC. Central nervous system paracoccidioidomycosis: clinical features and laboratorial findings. J Infect. 2004;48:193–8.
53. Marques da Silva SH, Colombo AL, Blotta MH, Lopes JD, Queiroz-Telles F, Pires de Camargo Z. Detection of circulating gp43 antigen in serum, cerebrospinal fluid, and bronchoalveolar lavage fluid of patients with paracoccidioidomycosis. J Clin Microbiol. 2003;41:3675–80.
54. Gasparetto EL, Liu CB, de Carvalho NA, Rogacheski E. Central nervous system paracoccidioidomycosis: imaging findings in 17 cases. J Comput Assist Tomogr. 2003;27:12–7.
55. Le T, Huu Chi N, Kim Cuc NT, Manh Sieu TP, Shikuma CM, Farrar J, et al. AIDS-associated Penicillium marneffei infection of the central nervous system. Clin Infect Dis: Off Pub Infect Dis Soc Am. 2010;51:1458–62.
56. Hu Y, Zhang J, Li X, Yang Y, Zhang Y, Ma J, et al. Penicillium marneffei infection: an emerging disease in mainland China. Mycopathologia. 2013;175:57–67.
57. Scott EN, Kaufman L, Brown AC, Muchmore HG. Serologic studies in the diagnosis and management of meningitis due to Sporothrix schenckii. N Engl J Med. 1987;317:935–40.
58. Hardman S, Stephenson I, Jenkins DR, Wiselka MJ, Johnson EM. Disseminated Sporothix schenckii in a patient with AIDS. J Infect. 2005;51:e73–7.
59. Cuomo CA, Rodriguez-Del Valle N, Perez-Sanchez L, Abouelleil A, Goldberg J, Young S, et al. Genome sequence of the pathogenic fungus Sporothrix schenckii (ATCC 58251). Genome Announc. 2014;2.
60. Kauffman CA, Bustamante B, Chapman SW, Pappas PG, Infectious Diseases Society of A. Clinical practice guidelines for the management of sporotrichosis: 2007 update by the infectious diseases society of America. Clin Infect Dis: Off Publ Infect Dis Soc Am. 2007;45:1255–65.
61. Rodrigues AM, de Hoog GS, de Cassia PD, Brihante RS, Sidrim JJ, Gadelha MF, et al. Genetic diversity and antifungal susceptibility profiles in causative agents of sporotrichosis. BMC Infect Dis. 2014;14:219.